265 related articles for article (PubMed ID: 31019020)
1. U.S. Food and Drug Administration Benefit-Risk Assessment of Nilotinib Treatment Discontinuation in Patients with Chronic Phase Chronic Myeloid Leukemia in a Sustained Molecular Remission.
Pulte ED; Wroblewski T; Bloomquist E; Tang S; Farrell A; Deisseroth A; McKee AE; Pazdur R
Oncologist; 2019 May; 24(5):e188-e195. PubMed ID: 31019020
[TBL] [Abstract][Full Text] [Related]
2. Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Single-Group, Phase 2, Open-Label Study.
Mahon FX; Boquimpani C; Kim DW; Benyamini N; Clementino NCD; Shuvaev V; Ailawadhi S; Lipton JH; Turkina AG; De Paz R; Moiraghi B; Nicolini FE; Dengler J; Sacha T; Takahashi N; Fellague-Chebra R; Acharya S; Wong S; Jin Y; Hughes TP
Ann Intern Med; 2018 Apr; 168(7):461-470. PubMed ID: 29459949
[TBL] [Abstract][Full Text] [Related]
3. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial.
Kantarjian HM; Hochhaus A; Saglio G; De Souza C; Flinn IW; Stenke L; Goh YT; Rosti G; Nakamae H; Gallagher NJ; Hoenekopp A; Blakesley RE; Larson RA; Hughes TP
Lancet Oncol; 2011 Sep; 12(9):841-51. PubMed ID: 21856226
[TBL] [Abstract][Full Text] [Related]
4. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease.
Rousselot P; Charbonnier A; Cony-Makhoul P; Agape P; Nicolini FE; Varet B; Gardembas M; Etienne G; Réa D; Roy L; Escoffre-Barbe M; Guerci-Bresler A; Tulliez M; Prost S; Spentchian M; Cayuela JM; Reiffers J; Chomel JC; Turhan A; Guilhot J; Guilhot F; Mahon FX
J Clin Oncol; 2014 Feb; 32(5):424-30. PubMed ID: 24323036
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of nilotinib 300 mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: Results from the Phase IIIb ENESTswift study.
Hiwase D; Tan P; D'Rozario J; Taper J; Powell A; Irving I; Wright M; Branford S; Yeung DT; Anderson L; Gervasio O; Levetan C; Roberts W; Solterbeck A; Traficante R; Hughes T
Leuk Res; 2018 Apr; 67():109-115. PubMed ID: 29494928
[TBL] [Abstract][Full Text] [Related]
6. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial.
Mahon FX; Réa D; Guilhot J; Guilhot F; Huguet F; Nicolini F; Legros L; Charbonnier A; Guerci A; Varet B; Etienne G; Reiffers J; Rousselot P;
Lancet Oncol; 2010 Nov; 11(11):1029-35. PubMed ID: 20965785
[TBL] [Abstract][Full Text] [Related]
7. Treatment-free remission after two-year consolidation therapy with nilotinib in patients with chronic myeloid leukemia: STAT2 trial in Japan.
Takahashi N; Nishiwaki K; Nakaseko C; Aotsuka N; Sano K; Ohwada C; Kuroki J; Kimura H; Tokuhira M; Mitani K; Fujikawa K; Iwase O; Ohishi K; Kimura F; Fukuda T; Tanosaki S; Takahashi S; Kameoka Y; Nishikawa H; Wakita H;
Haematologica; 2018 Nov; 103(11):1835-1842. PubMed ID: 29976734
[TBL] [Abstract][Full Text] [Related]
8. Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study.
Ross DM; Masszi T; Gómez Casares MT; Hellmann A; Stentoft J; Conneally E; Garcia-Gutierrez V; Gattermann N; le Coutre PD; Martino B; Saussele S; Giles FJ; Radich JP; Saglio G; Deng W; Krunic N; Bédoucha V; Gopalakrishna P; Hochhaus A
J Cancer Res Clin Oncol; 2018 May; 144(5):945-954. PubMed ID: 29468438
[TBL] [Abstract][Full Text] [Related]
9. Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia.
Deremer DL; Ustun C; Natarajan K
Clin Ther; 2008 Nov; 30(11):1956-75. PubMed ID: 19108785
[TBL] [Abstract][Full Text] [Related]
10. Nilotinib vs. imatinib in Japanese patients with newly diagnosed chronic myeloid leukemia in chronic phase: long-term follow-up of the Japanese subgroup of the randomized ENESTnd trial.
Nakamae H; Fukuda T; Nakaseko C; Kanda Y; Ohmine K; Ono T; Matsumura I; Matsuda A; Aoki M; Ito K; Shibayama H
Int J Hematol; 2018 Mar; 107(3):327-336. PubMed ID: 29076005
[TBL] [Abstract][Full Text] [Related]
11. Tasigna for chronic and accelerated phase Philadelphia chromosome--positive chronic myelogenous leukemia resistant to or intolerant of imatinib.
Hazarika M; Jiang X; Liu Q; Lee SL; Ramchandani R; Garnett C; Orr MS; Sridhara R; Booth B; Leighton JK; Timmer W; Harapanhalli R; Dagher R; Justice R; Pazdur R
Clin Cancer Res; 2008 Sep; 14(17):5325-31. PubMed ID: 18765523
[TBL] [Abstract][Full Text] [Related]
12. Nilotinib in the treatment of chronic myeloid leukemia.
Sacha T; Saglio G
Future Oncol; 2019 Mar; 15(9):953-965. PubMed ID: 30547682
[TBL] [Abstract][Full Text] [Related]
13. Expanding Nilotinib Access in Clinical Trials (ENACT): an open-label, multicenter study of oral nilotinib in adult patients with imatinib-resistant or imatinib-intolerant Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase.
Nicolini FE; Turkina A; Shen ZX; Gallagher N; Jootar S; Powell BL; De Souza C; Zheng M; Szczudlo T; le Coutre P
Cancer; 2012 Jan; 118(1):118-26. PubMed ID: 21732337
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of nilotinib in chronic myeloid leukaemia patients who failed to achieve a treatment-free remission period after imatinib discontinuation: Results of the French Nilo post-STIM study.
Dulucq S; Rigal-Huguet F; Nicolini FE; Cony-Makhoul P; Escoffre-Barbe M; Gardembas M; Legros L; Rousselot P; Liu J; Rea D; De Mas V; Hayette S; Raynaud S; Lacoste-Roussillon C; Robbesyn F; Klein E; Morisset S; Mahon FX; Etienne G
Br J Haematol; 2023 Jun; 201(6):1116-1124. PubMed ID: 37004981
[TBL] [Abstract][Full Text] [Related]
15. Cessation of nilotinib in patients with chronic myelogenous leukemia who have maintained deep molecular responses for 2 years: a multicenter phase 2 trial, stop nilotinib (NILSt).
Nagafuji K; Matsumura I; Shimose T; Kawaguchi T; Kuroda J; Nakamae H; Miyamoto T; Kadowaki N; Ishikawa J; Imamura Y; Yamazaki H; Akashi K; Kanakura Y
Int J Hematol; 2019 Dec; 110(6):675-682. PubMed ID: 31538327
[TBL] [Abstract][Full Text] [Related]
16. Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials.
Jain P; Kantarjian H; Alattar ML; Jabbour E; Sasaki K; Nogueras Gonzalez G; Dellasala S; Pierce S; Verstovsek S; Wierda W; Borthakur G; Ravandi F; O'Brien S; Cortes J
Lancet Haematol; 2015 Mar; 2(3):e118-28. PubMed ID: 26687797
[TBL] [Abstract][Full Text] [Related]
17. Budget impact analysis of treatment-free remission in nilotinib-treated Japanese chronic myeloid leukemia patients.
Yamazaki K; Inagaki N; Moldaver D; Viana R; Kimura S
Cancer Sci; 2020 Jul; 111(7):2526-2535. PubMed ID: 32324296
[TBL] [Abstract][Full Text] [Related]
18. U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval.
Cohen MH; Johnson JR; Pazdur R
Clin Cancer Res; 2005 Jan; 11(1):12-9. PubMed ID: 15671523
[TBL] [Abstract][Full Text] [Related]
19. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance.
Kantarjian HM; Giles F; Gattermann N; Bhalla K; Alimena G; Palandri F; Ossenkoppele GJ; Nicolini FE; O'Brien SG; Litzow M; Bhatia R; Cervantes F; Haque A; Shou Y; Resta DJ; Weitzman A; Hochhaus A; le Coutre P
Blood; 2007 Nov; 110(10):3540-6. PubMed ID: 17715389
[TBL] [Abstract][Full Text] [Related]
20. Impact of age on efficacy and toxicity of nilotinib in patients with chronic myeloid leukemia in chronic phase: ENEST1st subanalysis.
Giles FJ; Rea D; Rosti G; Cross NCP; Steegmann JL; Griskevicius L; le Coutre P; Coriu D; Petrov L; Ossenkoppele GJ; Mahon FX; Saussele S; Hellmann A; Koskenvesa P; Brümmendorf TH; Gastl G; Castagnetti F; Vincenzi B; Haenig J; Hochhaus A
J Cancer Res Clin Oncol; 2017 Aug; 143(8):1585-1596. PubMed ID: 28364360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
